EGFR and non-small cell lung carcinoma: showed a lack of association between EGFR mutation status and 11C-erlotinib uptake in an analysis of 10 NSCLC patients via dynamic multi-bed PET/CT scan using 11C-erlotinib, suggesting disease heterogeneity and low tracer uptake for the lack of association (66).